Keywords: encouraging, ph, iii, data, kyowa, hakko, pd

Encouraging Ph III data for Kyowa Hakko's PD drug

Article | 13 March 2006

Print This

Japanese drugmaker Kyowa Hakko Kogyo Co has completed three Phase III efficacy and safety studies of KW-6002 (istradefylline), an agent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in